Catalent (NYSE:CTLT) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Catalent (NYSE:CTLT) in a note issued to investors on Sunday. The brokerage set a “sell” rating on the stock.

Other equities research analysts also recently issued reports about the stock. Stephens reaffirmed an “equal weight” rating and issued a $63.50 target price on shares of Catalent in a research note on Thursday, April 4th. Barclays lifted their price target on shares of Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a research note on Friday. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $55.65.

Catalent Trading Down 0.3 %

Shares of CTLT opened at $56.23 on Friday. The firm’s 50 day simple moving average is $55.56 and its 200 day simple moving average is $53.86. The company has a market capitalization of $10.18 billion, a P/E ratio of -9.22 and a beta of 1.20. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.51 and a quick ratio of 1.77. Catalent has a 1-year low of $31.80 and a 1-year high of $60.20.

Catalent (NYSE:CTLT) last announced its earnings results on Wednesday, May 8th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.36). The company had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.11 billion. Catalent had a negative net margin of 26.61% and a negative return on equity of 2.73%. Sell-side analysts forecast that Catalent will post -0.17 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Ricky Hopson sold 1,401 shares of the business’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total transaction of $76,018.26. Following the completion of the transaction, the insider now directly owns 20,617 shares in the company, valued at approximately $1,118,678.42. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 0.31% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Mariner LLC boosted its position in shares of Catalent by 18.8% during the 3rd quarter. Mariner LLC now owns 13,079 shares of the company’s stock valued at $595,000 after acquiring an additional 2,073 shares during the last quarter. Natixis Advisors L.P. raised its position in Catalent by 22.1% during the third quarter. Natixis Advisors L.P. now owns 19,701 shares of the company’s stock valued at $897,000 after acquiring an additional 3,565 shares in the last quarter. Treasurer of the State of North Carolina raised its position in Catalent by 0.5% during the third quarter. Treasurer of the State of North Carolina now owns 81,729 shares of the company’s stock valued at $3,721,000 after acquiring an additional 421 shares in the last quarter. Tower Research Capital LLC TRC raised its position in Catalent by 102.0% during the third quarter. Tower Research Capital LLC TRC now owns 8,826 shares of the company’s stock valued at $402,000 after acquiring an additional 4,456 shares in the last quarter. Finally, Bank of Nova Scotia purchased a new position in Catalent during the third quarter valued at approximately $318,000.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.